Vericel Corporation (VCEL) is advancing in regenerative medicine with its MACI product, which repairs cartilage defects. The company is expanding capacity in Burlington to meet rising demand and has secured a BARDA contract supporting its Burn Care business. Upcoming potential launches in the UK and new ankle treatment indications could further drive growth. Despite a premium stock price, strong management execution and continued growth make VCEL a viable buy for investors.
BUILDon's price surged with a double-digit gain driven by a record 87,320 holders and a 39% volume increase to $17.3 million. Rising Open Interest and a high Funding Rate of 0.0179% in perpetual contracts indicate traders are betting on further price...
Coherent Corp. saw a 34% year-over-year revenue increase in Q4, surpassing expectations, with Q1 revenue forecasted to grow about 46% YoY. The company improved its gross margin to 40.2% and operating margin by 381 basis points, driven by pricing powe...
Ripple CEO Brad Garlinghouse supports the CLARITY Act, a US digital asset bill revised with 126 Democratic amendments covering ethics, DeFi oversight, and stablecoin regulations. The bill aims to protect community banks from deposit flight and split ...
Three public crypto treasury firms increased their holdings of Ethereum, Solana, and Bitcoin last week despite a soft market in September. BitMine Immersion Technologies added 27,180 ETH, nearing 5% of total supply, while DeFi Development Corp grew i...
Selkirk Copper Mines Inc. has filed an independent technical report updating the mineral resource estimate for its 100%-owned Minto Project in Yukon, Canada. The report, effective June 10, 2026, confirms no material changes from prior disclosed resul...
